<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00305838</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000463518</org_study_id>
    <secondary_id>CDR0000463518</secondary_id>
    <secondary_id>EU-205113</secondary_id>
    <secondary_id>NCRN-1509</secondary_id>
    <secondary_id>MREC-EC2003-62</secondary_id>
    <nct_id>NCT00305838</nct_id>
  </id_info>
  <brief_title>CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen</brief_title>
  <official_title>Use of Changes in CA 125 Doubling Time to Detect Activity of Cytostatic Agents in Women Relapsing With Ovarian Carcinoma. Study 1-Tamoxifen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mount Vernon Cancer Centre at Mount Vernon Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Estrogen may cause the growth of ovarian cancer cells. Hormone therapy using
      tamoxifen may fight ovarian cancer by blocking the use of estrogen by the tumor cells.
      Measuring CA 125 levels may help doctors predict a patient's response to tamoxifen and help
      plan the best treatment.

      PURPOSE: This phase II trial is studying CA 125 levels in treating patients with relapsed
      advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who are
      receiving tamoxifen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the percentage of patients with relapsed advanced ovarian carcinoma, fallopian
           tube carcinoma, or primary peritoneal carcinoma who have a log linear rise in CA 125
           levels.

        -  Determine whether the log linear part of the curve is consistent enough to allow
           comparison of the slope before and after introduction of a new therapy.

        -  Compare the serial doubling time before and after commencing tamoxifen citrate
           treatment.

        -  Determine the number of patients required to detect a significant difference in CA 125
           doubling time before and after starting tamoxifen citrate treatment.

      OUTLINE: Patients undergo blood collection once a month to measure CA 125 levels. Once the CA
      125 level goes above the upper limit of normal (ULN) or has started to rise from its nadir
      level (if not previously normal), CA 125 levels are measured every 2 weeks. When CA 125
      levels reach 4 times the ULN or 4 times the nadir level (if not previously normal), patients
      begin oral tamoxifen citrate once daily for 3-6 months in the absence of disease progression
      or unacceptable toxicity. CA 125 levels will continue to be measured every 2 weeks during
      treatment.

      PROJECTED ACCRUAL: A total of 200 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2004</start_date>
  <primary_completion_date type="Anticipated">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients who have a log linear rise in CA 125 levels</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of the slope before and after introduction of a new therapy in terms of consistency of the log linear part of the curve</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of the serial doubling time before and after commencing tamoxifen</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients required to detect a significant difference in CA 125 doubling time before and after starting tamoxifen</measure>
  </primary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Primary Peritoneal Cavity Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen citrate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>diagnostic laboratory biomarker analysis</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed advanced ovarian carcinoma, fallopian tube carcinoma, or
             primary peritoneal carcinoma

          -  Completed therapy for first relapse

               -  Had an elevated CA 125 level before starting relapse therapy with â‰¥ 50% fall by
                  completion of that therapy or response according to RECIST criteria

          -  No significant cancer-related symptoms requiring urgent treatment

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Life expectancy &gt; 3 months

          -  Hemoglobin &gt; 10 g/dL

          -  WBC &gt; 2,500/mm^3

          -  Platelet count &gt; 100,000/mm^3

          -  Creatinine &lt; 2 times upper limit of normal (ULN)

          -  AST/ALT &lt; 2 times ULN

          -  Bilirubin &lt; 1.5 times ULN

          -  No evidence of significant clinical disorder or laboratory finding that would preclude
             study participation

          -  No psychiatric disorder that would preclude informed consent

          -  Not pregnant or nursing

        PRIOR CONCURRENT THERAPY:

          -  No other concurrent hormonal therapy, except hormone-replacement therapy

          -  Other concurrent medications allowed provided dose is stable
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gordon J.S. Rustin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mount Vernon Cancer Centre at Mount Vernon Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen's Hospital</name>
      <address>
        <city>Burton-upon-Trent</city>
        <state>England</state>
        <zip>DE13 0RB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mojca Persic</last_name>
      <phone>44-1283-566-333</phone>
      <email>mojca.persic@derbyhospitals.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chelmsford and Essex Centre</name>
      <address>
        <city>Chelmsford</city>
        <state>England</state>
        <zip>CM2 0QH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1245-513-044</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Derby Hospital</name>
      <address>
        <city>Derby</city>
        <state>England</state>
        <zip>DE22 3NE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mojca Persic</last_name>
      <phone>44-1332-347-141</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Luke's Cancer Centre at Royal Surrey County Hospital</name>
      <address>
        <city>Guildford</city>
        <state>England</state>
        <zip>GU2 7XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas</last_name>
      <phone>44-1483-571-122</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ipswich Hospital</name>
      <address>
        <city>Ipswich</city>
        <state>England</state>
        <zip>IP4 5PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie S. Morgan, MBBS, FRCR, MRCP</last_name>
      <phone>44-1473-704-910</phone>
      <email>Jamie.Morgan@ipswichhospital.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Airedale General Hospital</name>
      <address>
        <city>Keighley</city>
        <state>England</state>
        <zip>BD20 6TD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>S. Michael Crawford, MD</last_name>
      <phone>44-1535-652-511</phone>
      <email>michael.crawford@anhst.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leeds Cancer Centre at St. James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tim J. Perren, MD</last_name>
      <phone>44-113-206-4670</phone>
      <email>t.j.perren@leeds.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liverpool Women's Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>England</state>
        <zip>LV8 7SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John A. Green, MD</last_name>
      <phone>44-151-708-9988</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher J. Gallagher, MD</last_name>
      <phone>44-20-7601-8521</phone>
      <email>chris.gallagher@bartsandthelondon.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clatterbridge Centre for Oncology</name>
      <address>
        <city>Merseyside</city>
        <state>England</state>
        <zip>CH63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John A. Green, MD</last_name>
      <phone>44-151-482-7743</phone>
      <email>john.green@ccotrust.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mount Vernon Cancer Centre at Mount Vernon Hospital</name>
      <address>
        <city>Northwood</city>
        <state>England</state>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gordon J.S. Rustin, MD</last_name>
      <phone>44-1923-844-389</phone>
      <email>grustin@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kings Mill Hospital</name>
      <address>
        <city>Nottinghamshire</city>
        <state>England</state>
        <zip>NG17 4JL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Santhanam Sundar</last_name>
      <phone>44-162-362-2515</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oxford Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <state>England</state>
        <zip>0X3 9DS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>T.S. Ganesan, MD</last_name>
      <phone>44-1865-222-458</phone>
      <email>ganesan@cancer.org.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wexham Park Hospital</name>
      <address>
        <city>Slough, Berkshire</city>
        <state>England</state>
        <zip>SL2 4HL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcia Hall, MD</last_name>
      <phone>44-1753-634-364</phone>
      <email>marcia.hall@nhs.net.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <state>England</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-23-8079-8751</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Great Western Hospital</name>
      <address>
        <city>Swindon</city>
        <state>England</state>
        <zip>SN3 6BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Horne</last_name>
      <phone>44-1793-604-020</phone>
      <email>amanda.horne@orh.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hillingdon Hospital</name>
      <address>
        <city>Uxbridge</city>
        <state>England</state>
        <zip>UB8 3NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1923-844-190</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>NHS Grampian</name>
      <address>
        <city>Aberdeen</city>
        <state>Scotland</state>
        <zip>AB25 2ZB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Parkin</last_name>
      <phone>44-122-455-3659</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <state>Scotland</state>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1224-553-659</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Glasgow University Hospitals NHS Trust</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G21 3UR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas S. Reed, MD</last_name>
      <phone>44-141-301-7057</phone>
      <email>nick.reed@northglasgow.scot.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ysbyty Gwynedd</name>
      <address>
        <city>Bangor</city>
        <state>Wales</state>
        <zip>LL57 2PW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1248-384-331</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Velindre Cancer Center at Velindre Hospital</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF4 7XL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malcolm Adams, MD</last_name>
      <phone>44-29-2061-5888 ext. 6204</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glan Clwyd Hospital</name>
      <address>
        <city>Rhyl, Denbighshire</city>
        <state>Wales</state>
        <zip>LL 18 5UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1745-583-910</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wrexham Maelor Hospital</name>
      <address>
        <city>Wrexham</city>
        <state>Wales</state>
        <zip>LL13 7TD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1978-291-100</phone>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2006</study_first_submitted>
  <study_first_submitted_qc>March 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2006</study_first_posted>
  <last_update_submitted>August 9, 2013</last_update_submitted>
  <last_update_submitted_qc>August 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2013</last_update_posted>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>stage IIIA ovarian epithelial cancer</keyword>
  <keyword>stage IIIB ovarian epithelial cancer</keyword>
  <keyword>stage IIIC ovarian epithelial cancer</keyword>
  <keyword>recurrent fallopian tube cancer</keyword>
  <keyword>stage IIIA fallopian tube cancer</keyword>
  <keyword>stage IIIB fallopian tube cancer</keyword>
  <keyword>stage IIIC fallopian tube cancer</keyword>
  <keyword>stage IV fallopian tube cancer</keyword>
  <keyword>recurrent primary peritoneal cavity cancer</keyword>
  <keyword>stage IIIA primary peritoneal cavity cancer</keyword>
  <keyword>stage IIIB primary peritoneal cavity cancer</keyword>
  <keyword>stage IIIC primary peritoneal cavity cancer</keyword>
  <keyword>stage IV primary peritoneal cavity cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

